{"id":"intravenous-levetireacetam","safety":{"commonSideEffects":[{"rate":"15-30","effect":"Somnolence"},{"rate":"10-15","effect":"Asthenia/fatigue"},{"rate":"10-15","effect":"Dizziness"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Behavioral/mood changes"},{"rate":"5-10","effect":"Infection"},{"rate":"3-5","effect":"Ataxia"}]},"_chembl":{"chemblId":"CHEMBL2109039","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Levetiracetam is a pyrrolidone derivative that binds to the synaptic vesicle protein SV2A, which is involved in vesicle exocytosis and neurotransmitter release. This binding reduces the release of excitatory neurotransmitters and stabilizes neuronal membranes, thereby suppressing seizure propagation. The exact mechanism remains incompletely understood, but SV2A binding is considered the primary molecular action responsible for its anticonvulsant effects.","oneSentence":"Levetiracetam reduces neuronal excitability and seizure activity through binding to synaptic vesicle protein SV2A, modulating neurotransmitter release.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:49:52.640Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Adjunctive therapy for partial-onset seizures"},{"name":"Adjunctive therapy for myoclonic seizures in patients with juvenile myoclonic epilepsy"},{"name":"Adjunctive therapy for primary generalized tonic-clonic seizures"}]},"trialDetails":[{"nctId":"NCT04829838","phase":"PHASE4","title":"Comparison of Efficacy of Phenytoin With Levetireacetam for the Management of Children With Status Epilepticus","status":"UNKNOWN","sponsor":"ayesha tariq","startDate":"2019-07-25","conditions":"Status Epilepticus","enrollment":244},{"nctId":"NCT04176887","phase":"PHASE4","title":"Levetiracetam Versus Phenytoin in Management of Pediatric Status Epilepticus","status":"UNKNOWN","sponsor":"Tanta University","startDate":"2019-01-01","conditions":"Comparison, the Efficacy of Levetireacetam, Phenytoin","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"intravenous levetireacetam","genericName":"intravenous levetireacetam","companyName":"ayesha tariq","companyId":"ayesha-tariq","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Levetiracetam reduces neuronal excitability and seizure activity through binding to synaptic vesicle protein SV2A, modulating neurotransmitter release. Used for Adjunctive therapy for partial-onset seizures, Adjunctive therapy for myoclonic seizures in patients with juvenile myoclonic epilepsy, Adjunctive therapy for primary generalized tonic-clonic seizures.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}